Biofrontera AGFRA:B8FK 56 Net Margin % is 59.24% as of Mar. 2026. GuruFocus rates FRA:B8FK with a GF Score™ of 56/100 and a GF Value™ of €2.29 (Fairly Valued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Biofrontera AG ranks worse than 80.54% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Biofrontera AG's Net Income for the
three
months ended in Mar. 2026 was €2.20 Mil. Biofrontera AG's Revenue for the
three
months ended in Mar. 2026 was €3.71 Mil. Therefore, Biofrontera AG's net margin for the quarter that ended in Mar. 2026 was 59.24%.
The historical rank and industry rank for Biofrontera AG's Net Margin % or its related term are showing as below:
FRA:B8FK'
s Net Margin % Range Over the Past 10 Years
Min: -172.58 Med: -38.89 Max: 131.13
Current: -17.92
FRA:B8FK's Net Margin % is ranked worse than 80.54% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:B8FK: -17.92
Biofrontera AG (FRA:B8FK) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biofrontera AG Net Margin % Related Terms
Biofrontera AG Net Margin % Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:B8FK vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (FRA:B8FK) has a Net Margin % of 59.24% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #770 out of 956 companies in the Drug Manufacturers industry, placing it in the top 80.5%.
Is Biofrontera AG's Net Margin % too high?
Biofrontera AG's current Net Margin % is 59.24%. The Drug Manufacturers industry median Net Margin % is 5.56. Biofrontera AG's value of 59.24% is 965.5% above this industry median. Based on the distribution chart, Biofrontera AG ranks #770 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #770 out of 956 companies for Net Margin %. This places Biofrontera AG in the lower half of its industry. The industry median Net Margin % is 5.56. Biofrontera AG's value of 59.24% is 965.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Net Margin % of 59.24% is 965.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Net Margin % is 59.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.21 — trading 3.5% below its estimated fair value. The current Net Margin % is 59.24% and 965.5% above the Drug Manufacturers industry median of 5.56. Biofrontera AG's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current Net Margin % is 59.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for FRA:B8FK:
Net Margin %: 59.24%
GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
Industry Position: 965.5% above the Drug Manufacturers median (#770 of 956)
No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
56GF Score
Get the complete analysis for FRA:B8FK
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B8FK has been successfully added to your 
